Assertio Holdings initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Assertio Holdings with a Buy rating and $4 price target. Assertio “has long been underrated and overlooked due to its checkered history,” the analyst tells investors in a research note. The firm considers the stock undervalued and believes that in the long run positive traction with key products like Rolvedon, Otrexup and Sympazan “ought to drive renewed interest from investors.”